Consensus on the Therapeutic Management of Atopic Dermatitis - Brazilian Society of Dermatology

Background: Atopic dermatitis is a highly prevalent inflammatory and pruritic dermatosis with a multifactorial etiology, which includes skin barrier defects, immune dysfunction, and microbiome alterations. Atopic dermatitis is mediated by genetic, environmental, and psychological factors and requires therapeutic management that covers all the aspects of its complex pathogenesis.

Objectives: The aim of this article is to present the experience, opinions, and recommendations of Brazilian dermatology experts regarding the therapeutic management of atopic dermatitis.

Methods: Eighteen experts from 10 university hospitals with experience in atopic dermatitis were appointed by the Brazilian Society of Dermatology to organize a consensus on the therapeutic management of atopic dermatitis. The 18 experts answered an online questionnaire with 14 questions related to the treatment of atopic dermatitis. Afterwards, they analyzed the recent international guidelines on atopic dermatitis of the American Academy of Dermatology, published in 2014, and of the European Academy of Dermatology and Venereology, published in 2018. Consensus was defined as approval by at least 70% of the panel.

Results/conclusion: The experts stated that the therapeutic management of atopic dermatitis is based on skin hydration, topical anti-inflammatory agents, avoidance of triggering factors, and educational programs. Systemic therapy, based on immunosuppressive agents, is only indicated for severe refractory disease and after failure of topical therapy. Early detection and treatment of secondary bacterial and viral infections is mandatory, and hospitalization may be needed to control atopic dermatitis flares. Novel target-oriented drugs such as immunobiologicals are invaluable therapeutic agents for atopic dermatitis.

Citing Articles

A systematic review of guidelines for the management of atopic dermatitis in children.

Deva M, Netting M, Weidinger J, Brand R, Loh R, Vale S World Allergy Organ J. 2024; 17(12):100989.

PMID: 39634513 PMC: 11613179. DOI: 10.1016/j.waojou.2024.100989.

International consensus on methotrexate dosing for patients with atopic dermatitis: An eDelphi study.

Caron A, van Huizen A, Musters A, Gerbens L, Middelkamp Hup M, Flohr C J Eur Acad Dermatol Venereol. 2024; 39(2):331-339.

PMID: 39087636 PMC: 11761001. DOI: 10.1111/jdv.20271.

Methotrexate for refractory adult atopic dermatitis leads to alterations in cutaneous IL-31 and IL-31RA expression.

Samorano L, Manfrere K, Pereira N, Takaoka R, Valente N, Sotto M An Bras Dermatol. 2023; 99(1):72-79.

PMID: 37730501 PMC: 10964359. DOI: 10.1016/j.abd.2023.01.002.

The PI3K-Akt-mTOR and Associated Signaling Pathways as Molecular Drivers of Immune-Mediated Inflammatory Skin Diseases: Update on Therapeutic Strategy Using Natural and Synthetic Compounds.

Roy T, Boateng S, Uddin M, Banang-Mbeumi S, Yadav R, Bock C Cells. 2023; 12(12).

PMID: 37371141 PMC: 10297376. DOI: 10.3390/cells12121671.

Consensus on the therapeutic management of atopic dermatitis ‒ Brazilian Society of Dermatology: an update on phototherapy and systemic therapy using e-Delphi technique.

Orfali R, Lorenzini D, Bressan A, Tanaka A, Cerqueira A, Hirayama A An Bras Dermatol. 2023; 98(6):814-836.

PMID: 37302894 PMC: 10589461. DOI: 10.1016/j.abd.2023.04.003.

References

Wollenberg A, Reitamo S, Girolomoni G, Lahfa M, Ruzicka T, Healy E . Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment. Allergy. 2008; 63(7):742-50. View

Cuomo B, Indirli G, Bianchi A, Arasi S, Caimmi D, Dondi A . Specific IgE and skin prick tests to diagnose allergy to fresh and baked cow's milk according to age: a systematic review. Ital J Pediatr. 2017; 43(1):93. PMC: 5639767. DOI: 10.1186/s13052-017-0410-8. View

Herro E, Matiz C, Sullivan K, Hamann C, Jacob S . Frequency of contact allergens in pediatric patients with atopic dermatitis. J Clin Aesthet Dermatol. 2011; 4(11):39-41. PMC: 3225137. View

Diepgen T . Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol. 2002; 13(4):278-86. DOI: 10.1034/j.1399-3038.2002.01047.x. View

Lee D, Clark A, Tran K, Shi V . New and emerging targeted systemic therapies: a new era for atopic dermatitis. J Dermatolog Treat. 2017; 29(4):364-374. DOI: 10.1080/09546634.2017.1373736. View

Weber M, Lorenzini D, Reinehr C, Lovato B . Assessment of the quality of life of pediatric patients at a center of excellence in dermatology in southern Brazil. An Bras Dermatol. 2012; 87(5):697-702. DOI: 10.1590/s0365-05962012000500004. View

Sole D, Camelo-Nunes I, Wandalsen G, Mallozi M, Naspitz C . Prevalence of atopic eczema and related symptoms in Brazilian schoolchildren: results from the International Study of Asthma and Allergies in Childhood (ISAAC) phase 3. J Investig Allergol Clin Immunol. 2006; 16(6):367-76. View

Kong H, Oh J, Deming C, Conlan S, Grice E, Beatson M . Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res. 2012; 22(5):850-9. PMC: 3337431. DOI: 10.1101/gr.131029.111. View

Simpson E, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L . Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol. 2016; 75(3):506-515. DOI: 10.1016/j.jaad.2016.04.054. View

10.

Thaci D, Reitamo S, Gonzalez Ensenat M, Moss C, Boccaletti V, Cainelli T . Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. Br J Dermatol. 2008; 159(6):1348-56. DOI: 10.1111/j.1365-2133.2008.08813.x. View

11.

Takaoka R, Aoki V . Education of Patients with Atopic Dermatitis and Their Caregivers. Pediatr Allergy Immunol Pulmonol. 2022; 29(4):160-163. DOI: 10.1089/ped.2016.0702. View

12.

Sun D, Ong P . Infectious Complications in Atopic Dermatitis. Immunol Allergy Clin North Am. 2016; 37(1):75-93. DOI: 10.1016/j.iac.2016.08.015. View

13.

Walsh P, Aeling J, Huff L, Weston W . Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol. 1993; 29(3):501-3. DOI: 10.1016/s0190-9622(08)82011-7. View

14.

Staab D, von Rueden U, Kehrt R, Erhart M, Wenninger K, Kamtsiuris P . Evaluation of a parental training program for the management of childhood atopic dermatitis. Pediatr Allergy Immunol. 2002; 13(2):84-90. DOI: 10.1034/j.1399-3038.2002.01005.x. View

15.

Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A . Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018; 32(6):850-878. DOI: 10.1111/jdv.14888. View

16.

van der Schaft J, Politiek K, van den Reek J, Christoffers W, Kievit W, de Jong E . Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis. Br J Dermatol. 2015; 172(6):1621-1627. DOI: 10.1111/bjd.13730. View

17.

Grice E, Kong H, Conlan S, Deming C, Davis J, Young A . Topographical and temporal diversity of the human skin microbiome. Science. 2009; 324(5931):1190-2. PMC: 2805064. DOI: 10.1126/science.1171700. View

18.

Watson W, Kapur S . Atopic dermatitis. Allergy Asthma Clin Immunol. 2011; 7 Suppl 1:S4. PMC: 3245437. DOI: 10.1186/1710-1492-7-S1-S4. View

19.

Bath-Hextall F, Delamere F, Williams H . Dietary exclusions for improving established atopic eczema in adults and children: systematic review. Allergy. 2009; 64(2):258-64. DOI: 10.1111/j.1398-9995.2008.01917.x. View

20.

Arellano F, Wentworth C, Arana A, Fernandez C, Paul C . Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2006; 127(4):808-16. DOI: 10.1038/sj.jid.5700622. View